Per mL Lidocaine HCl 50 mg, phenylephrine HCl 5 mg
Indications/Uses
Topical anaesth & local vasoconstriction prior to endoscopy of the upper airways. Prep of nasal mucosa for surgery. Aid in the treatment of acute nose bleeds & removal of foreign bodies from the nose. Topical anaesth of the pharynx prior to direct or indirect laryngoscopy.
Patients w/ comorbidities should be given a reduced dose. Hyperthyroidism & CV disease, especially those suffering from HTN, severe bradycardia, conduction disturbance or severe digitalis intoxication. Adverse cardiac effects on patients w/ epilepsy who are on phenytoin. Genetic predisposition to malignant hyperthermia & preexisting abnormal neurological conditions. Careful monitoring of CV & resp vital signs should be done. Patient w/ cuts or sores in areas of nose or throat may cause higher drug level in the blood. Carefully exam the nose & throat before the procedure. Avoid use in presence of severe infection or severely traumatized mucosa in the areas of application. Food or drinks especially hot liqd should not be ingested w/in 2 hr of use. May cause allergic-type reactions w/ Na metabisulfite. Contains Na metabisulfite. Hepatic insufficiency. Renal impairment. Phenylephrine HCl: Patients taking MAOIs or w/in 2-3 wk after discontinuation. Risk of inducing closed angle glaucoma.
Lidocaine HCl: Reduced clearance w/ propranolol or cimetidine. Additive or antagonistic effect w/ antiarrhythmics. Prolongs the action of suxamethonium. Additive cardiac depressant effects w/ phenytoin. Phenylephrine HCl: May increase risk of high BP w/ TCAs. May increase effect w/ MAOIs. Reduced or reverse the pressor effect w/ phenothiazines & butyrophenones.
Sign Out
